News tagged with lenalidomide

Related topics: patients · multiple myeloma

New myeloma treatment options show promise

(HealthDay)—New multiple myeloma treatment options appear promising for patients aged 65 years and younger and for newly diagnosed patients who are ineligible for stem-cell transplantation, according to two studies published ...

Sep 04, 2014
popularity0 comments 0

Treatment beneficial in smoldering multiple myeloma

(HealthDay)—For patients with smoldering multiple myeloma, treatment with lenalidomide plus dexamethasone correlates with delayed progression and improved survival, according to a study published in the Aug. 1 issue of ...

Aug 01, 2013
popularity0 comments 0

New drug improves survival in multiple myeloma relapse

Researchers at Moffitt Cancer Center and colleagues have investigated the safety, efficacy and the maximum tolerated dose of pomalidomide for patients with multiple myeloma who have disease relapsed after treatments with ...

Jan 24, 2013
popularity0 comments 0


Lenalidomide ( /lɛnəˈlɪdɵmaɪd/), initially known as CC-5013 and marketed as Revlimid by Celgene, is a derivative of thalidomide introduced in 2004.

It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic treatment. Lenalidomide has also shown efficacy in the class of hematological disorders known as myelodysplastic syndromes (MDS). Lenalidomide and bortezomib are considered therapeutic breakthroughs in the treatment of myeloma, which generally carries a poor prognosis.

This text uses material from Wikipedia, licensed under CC BY-SA

Subscribe to rss feed